Retrospective Study on Microbial Diversity in Paraffin Tissue of Pancreatic Diseases

Launched by RUIJIN HOSPITAL · Dec 31, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the types of bacteria and other microorganisms present in the tissue of patients with pancreatic diseases, including pancreatic cancer. Researchers believe that these microorganisms may play a role in how these diseases develop and progress. By examining the differences in microbial communities in pancreatic tissues, the study aims to provide new insights that could help with earlier diagnosis and treatment options for pancreatic diseases.

To participate in this study, individuals should be between 5 and 85 years old and have a clear diagnosis of pancreatic cancer or other pancreatic diseases confirmed by surgery. Participants should not have taken antibiotics or probiotic yogurt in the three months leading up to their surgery, and they should have stable heart, liver, and kidney functions. Throughout the trial, participants can expect to contribute to valuable research that may help improve understanding and treatment of pancreatic diseases in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 5 years old, ≤ 85 years old;
• • After MDT discussion, routine surgery can be performed, and the postoperative pathology is clear as pancreatic cancer and other pancreatic diseases;
• • No history of antibiotics for three months before surgery, no history of yogurt containing probiotics
• • There is no serious damage to heart, liver and kidney function.
• Exclusion Criteria:
• • Antibiotics or yogurt containing probiotics history in three months;
• • Patients with evidence of sensory or motor neuropathy;
• • Those who have a clear cardiovascular disease, severe associated disease or active infection, including known HIV infection;
• • Those who have a history of other cancers.